Efficacy of nitazoxanide against cryptosporidium parvum in cell culture and in animal models

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 8, 1998, Pages 1959-1965

  Theodos, Cynthia M ^a   Griffiths, Jeffrey K ^a,b   D'Onfro, Jennifer ^a   Fairfield, Alexandra ^c   Tzipori, Saul ^a  

^a TUFTS UNIVERSITY   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; NITAZOXANIDE; PAROMOMYCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIMICROBIAL ACTIVITY; ARTICLE; CELL CULTURE; CONTROLLED STUDY; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM PARVUM; DIARRHEA; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SCREENING; EXPERIMENTAL INFECTION; INTESTINE MUCOSA; MOUSE; NONHUMAN; OOCYST; PRIORITY JOURNAL; SWINE;

EID: 0031928704     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.8.1959     Document Type: Article

References (20)

1. Blagburn, B. L., and R. Soave. 1997. Prophylaxis and chemotherapy: human and animal, p. 111-128. In R. Fayer (ed.), Cryptosporidium and cryptosporidiosis - 1997. CRC Press, Boca Raton, Fla.
2. Cavier, R., and J. F. Rossignol. 1982. Pharmacological study of various antihelminthic combinations. Rev. Med. Vet. 133:779-783.
3. Current, W. L. 1990. Techniques and laboratory maintenance of Cryptosporidium, p. 31-49. In J. P. Pubey, C. A. Speer, and R. Fayer (ed.), Cryptosporidiosis of man and animals. CRC Press, Boston, Mass.
4. Davis, L. J., R. Soave, R. E. Dudley, J. W. Fessel, S. Faulkner, and J. P. Mamakos. 1996. Nitazoxanide (NTZ) for AIDS-related cryptosporidial diarrhea (CD): an open-label safety, efficacy and pharmacokinetic study, abstr. LM50, p. 289. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
5. Doumbo, O., J. F. Rossignol, E. Pichard, et al. 1997. Nitazoxanide in treatment of cryptosporidial diarrhea and other intestinal parasitic infections associated with acquired immunodeficiency syndrome in tropical Africa. Am. J. Trop. Med. Hyg. 56:637-639.
6. Dubreuil, L., I. Houcke, Y. Mouton, and J.-F. Rossignol. 1996. In vitro evaluation of activities of nitazoxanide and tizoxanide against anaerobes and aerobic organisms. Antimicrob. Agents Chemother. 40:2266-2270.
7. Eggleston, M. T., M. Tilley, and S. J. Upton. 1994. Enhanced development of Cryptosporidium parvum in vitro by removal of oocyst toxins from infected cell monolayers. J. Helminthol. Soc. Wash. 61:122-125.
8. Euzeby, J., S. Prom-Tep, and J. F. Rossignol. 1980. Study of the antihelminthic properties of nitazoxanide in dog, cat and sheep. Rev. Med Vet. 131: 687-696.
9. Feregrino, G. M., R. F. Higuera, J. F. Rossignol, et al. 1996. Extraordinary potency of the nitazoxanida. A new antiparisitary against the Cryptosporidium parvum infections in advanced AIDS. In Abstracts from the XIth International Conference on AIDS, Vancouver, Canada.
10. Flanigan, T., R. Marshall, D. Redman, C. Kaetzel, and B. Ungar. 1991. In vitro screening of therapeutic agents against Cryptosporidium: hyperimmune cow colostrum is highly inhibitory. J. Protozool. 38:225S-227S.
11. Giacometti, A., O. Cirioni, and G. Scalise. 1996. In vitro activity of macrolides alone and in combination with artemisin, atovaquone, dapsone, minocycline or pyrimethamine against Cryptosporidium parvum. J. Antimicrob. Chemother. 38:399-408.
12. Griffiths, J. K., R. Moore, S. Dooley, G. T. Keusch, and S. Tzipori. 1994. Cryptosporidium parvum infection of Caco-2 cell monolayers induces an apical monolayer defect, selectively increases transmonolayer permeability, and causes epithelial cell death. Infect. Immun. 62:4506-4514.
13. Griffiths, J. K. 1998. Human cryptosporidiosis: epidemiology, transmission, clinical disease, treatment and diagnosis. Adv. Parasitol. 40:37-85.
14. McDonald, V., R. Stables, D. C. Warhurst, M. R. Barer, D. A. Blewett, H. D. Chapman, G. M. Connolly, P. L. Chiodini, and K. P. W. J. McAdam. 1990. In vitro cultivation of Cryptosporidium parvum and screening for anticryptosporidial drugs. Antimicrob. Agents Chemother. 34:1498-1500.
15. O'Donoghue, P. J. 1995. Cryptosporidium and cryptosporidiosis in man and animals. Int. J. Parasitol. 25:139-195.
16. Rossignol, J. F., and H. Maisonneuve. 1984. Nitazoxanide in the treatment of Taenia saginata and Hymenolepis nana infections. Am. J. Trop. Med. Hyg. 33:511-512.
17. Tzipori, S., W. Rand, J. Griffiths, G. Widmer, and J. Crabb. 1994. Evaluation of an animal model system for cryptosporidiosis: therapeutic efficacy of paromomycin and hyperimmune bovine colostrum-immunoglobulin. Clin. Diagn. Lab. Immunol. 1:450-463.
18. Tzipori, S., W. Rand, and C. Theodos. 1995. Evaluation of a two-phase scid mouse model preconditioned with anti-interferon-γ monoclonal antibody for drug testing against Cryptosporidium parvum. J. Infect. Dis. 172:1160-1164.
19. Tzipori, S. 1998. Cryptosporidium parvum: laboratory investigations and chemotherapy. Adv. Parasitol. 40:188-221.
20. Woods, K. M., M. V. Nesterenko, and S. J. Upton. 1996. Efficacy of 101 antimicrobials and other agents in the development of Cryptosporidium parvum in vitro. Ann. Trop. Med. Parasitol. 60:603-615.